CapLaw-2026-30

CRISPR Therapeutics‘s Issuance of USD 600 MillionConvertible Senior Notes

8 May 2026

News, Deals & Cases

On 16 March 2026, CRISPR Therapeutics AG issued a USD 600 million aggregate principal amount of convertible senior notes with a semiannual effective coupon of 1.7308% due 2031

By
CapLaw

Reference: CapLaw-2026-30

Read more: CRISPR Therapeutics‘s Issuance of USD 600 MillionConvertible Senior Notes